Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Equity Average (2020 - 2022)

Atea Pharmaceuticals has reported Equity Average over the past 3 years, most recently at $661.8 million for Q3 2022.

  • Quarterly results put Equity Average at $661.8 million for Q3 2022, up 12.24% from a year ago — trailing twelve months through Sep 2022 was $661.8 million (up 12.24% YoY), and the annual figure for FY2021 was $628.9 million, changed.
  • Equity Average for Q3 2022 was $661.8 million at Atea Pharmaceuticals, down from $670.2 million in the prior quarter.
  • Over the last five years, Equity Average for AVIR hit a ceiling of $695.0 million in Q1 2022 and a floor of -$69.8 million in Q3 2020.
  • Median Equity Average over the past 3 years was $590.9 million (2021), compared with a mean of $452.9 million.
  • Biggest five-year swings in Equity Average: soared 1116.44% in 2021 and later rose 12.24% in 2022.
  • Atea Pharmaceuticals' Equity Average stood at $235.6 million in 2020, then soared by 174.04% to $645.8 million in 2021, then increased by 2.49% to $661.8 million in 2022.
  • The last three reported values for Equity Average were $661.8 million (Q3 2022), $670.2 million (Q2 2022), and $695.0 million (Q1 2022) per Business Quant data.